Biocept Future Growth
Future criteria checks 2/6
Biocept is forecast to grow earnings and revenue by 56.6% and 67.1% per annum respectively while EPS is expected to grow by 77.3% per annum.
Key information
56.6%
Earnings growth rate
77.3%
EPS growth rate
Biotechs earnings growth | 28.4% |
Revenue growth rate | 67.1% |
Future return on equity | n/a |
Analyst coverage | Low |
Last updated | 21 Sep 2023 |
Recent future growth updates
Recent updates
Biocept, Inc. (NASDAQ:BIOC) Shares Fly 48% But Investors Aren't Buying For Growth
Apr 17Statutory Earnings May Not Be The Best Way To Understand Biocept's (NASDAQ:BIOC) True Position
Nov 23Just In: One Analyst Has Become A Lot More Bullish On Biocept, Inc.'s (NASDAQ:BIOC) Earnings
Aug 19Shareholders Will Probably Hold Off On Increasing Biocept, Inc.'s (NASDAQ:BIOC) CEO Compensation For The Time Being
Jul 03Biocept and CLEARED4 ink collaboration agreement
Jun 09Biocept enters COVID-19 testing partnership
Apr 28Biocept (NASDAQ:BIOC) Shareholders Have Enjoyed An Impressive 104% Share Price Gain
Mar 13We're Keeping An Eye On Biocept's (NASDAQ:BIOC) Cash Burn Rate
Jan 26Biocept, Inc. (NASDAQ:BIOC): Is Breakeven Near?
Dec 22Biocept's assays viable and sensitive for detecting tumor cells and biomarkers
Nov 20Biocept +4% on COVID-19 testing update
Nov 12Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
12/31/2025 | 21 | -17 | N/A | N/A | 1 |
12/31/2024 | 6 | -23 | N/A | N/A | 1 |
12/31/2023 | 2 | -22 | N/A | N/A | 1 |
6/30/2023 | 1 | -31 | -18 | -18 | N/A |
3/31/2023 | 7 | -37 | -19 | -19 | N/A |
12/31/2022 | 26 | -32 | -14 | -13 | N/A |
9/30/2022 | 41 | -25 | -9 | -7 | N/A |
6/30/2022 | 57 | -16 | -5 | -4 | N/A |
3/31/2022 | 63 | -8 | 1 | 2 | N/A |
12/31/2021 | 61 | -3 | 2 | 4 | N/A |
9/30/2021 | 66 | 2 | -1 | 1 | N/A |
6/30/2021 | 55 | -2 | -7 | -5 | N/A |
3/31/2021 | 44 | -7 | -15 | -14 | N/A |
12/31/2020 | 27 | -18 | -21 | -20 | N/A |
9/30/2020 | 11 | -25 | -25 | -24 | N/A |
6/30/2020 | 6 | -26 | -24 | -23 | N/A |
3/31/2020 | 6 | -28 | -24 | -23 | N/A |
12/31/2019 | 6 | -25 | -24 | -23 | N/A |
9/30/2019 | 5 | -26 | -23 | -23 | N/A |
6/30/2019 | 4 | -27 | -23 | -23 | N/A |
3/31/2019 | 3 | -25 | -22 | -22 | N/A |
12/31/2018 | 3 | -25 | -23 | -22 | N/A |
9/30/2018 | 3 | -25 | -23 | -23 | N/A |
6/30/2018 | 4 | -24 | -23 | -22 | N/A |
3/31/2018 | 4 | -24 | -23 | -21 | N/A |
12/31/2017 | 5 | -22 | -21 | -20 | N/A |
9/30/2017 | 5 | -20 | -19 | -18 | N/A |
6/30/2017 | 5 | -19 | -17 | -16 | N/A |
3/31/2017 | 5 | -18 | N/A | -15 | N/A |
12/31/2016 | 3 | -18 | N/A | -16 | N/A |
9/30/2016 | 2 | -19 | N/A | -16 | N/A |
6/30/2016 | 1 | -19 | N/A | -16 | N/A |
3/31/2016 | 1 | -18 | N/A | -16 | N/A |
12/31/2015 | 1 | -17 | N/A | -15 | N/A |
9/30/2015 | 0 | -16 | N/A | -14 | N/A |
6/30/2015 | 0 | -16 | N/A | -14 | N/A |
3/31/2015 | 0 | -15 | N/A | -13 | N/A |
12/31/2014 | 0 | -16 | N/A | -15 | N/A |
9/30/2014 | 0 | -14 | N/A | -13 | N/A |
6/30/2014 | 0 | -13 | N/A | -11 | N/A |
3/31/2014 | 0 | -12 | N/A | -10 | N/A |
12/31/2013 | 0 | -9 | N/A | -6 | N/A |
9/30/2013 | 0 | -10 | N/A | -7 | N/A |
6/30/2013 | 0 | -10 | N/A | -7 | N/A |
3/31/2013 | 0 | -11 | N/A | -8 | N/A |
12/31/2012 | 0 | -12 | N/A | -9 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: BIOC is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: BIOC is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: BIOC is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: BIOC's revenue (67.1% per year) is forecast to grow faster than the US market (8.1% per year).
High Growth Revenue: BIOC's revenue (67.1% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if BIOC's Return on Equity is forecast to be high in 3 years time